SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (323)6/24/1999 3:41:00 PM
From: tuck   of 496
 
NI,

Hey, that's what these forums are for. I never said my list of competitors in either area was exhaustive, just what I -- only a bit more informed than average -- had uncovered in my DD. I can't remember the big Pharma, or the Austrian company (info was quite vague on these, anyhow, as I recall), but I could find both if you're curious.

I've heard of CEPH and VRTX's programs, but they aren't in trials, either. NEOT appeared to be farther along than anyone in terms of bringing such a drug to market.

In terms of the science behind these various companies' neurotrophin compounds, how do you think GLFD stacks up? Or do you charge for that kind opining?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News